OPRXHealthcare · Health Information ServicesThe 6 Wall Street analysts covering OptimizeRx Corp. hold a median 12-month price target of $11 — +38.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 2 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OptimizeRx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (89): The business earns solid, repeatable profits on what it owns.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +38.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | $9.00 → $11 |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | $11 → $10 |
| 13 May 2026 | Lake Street | Maintains | Buy | — |
| 13 May 2026 | Lake Street | Maintains | Buy | $20 → $11 |
| 13 May 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 13 May 2026 | Stephens & Co. | Maintains | Equal-Weight | $10 → $7.00 |
| 13 May 2026 | Stifel | Maintains | Buy | $17 → $14 |
| 13 May 2026 | Stifel | Maintains | Buy | — |
| 6 Mar 2026 | B. Riley Securities | Reiterates | Buy | — |
| 6 Mar 2026 | Lake Street | Maintains | Buy | — |
| 6 Mar 2026 | Roth Capital | Maintains | Buy | — |
| 6 Mar 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 6 Mar 2026 | Stifel | Maintains | Buy | — |
| 17 Nov 2025 | Stephens & Co. | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 10 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
| 11 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 8 Aug 2025 | Stifel | Maintains | Buy | — |
| 9 June 2025 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, OptimizeRx Corp. returned −54.7% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 25% of US stocks
Cheaper than 60% of US stocks
Cheaper than 70% of US stocks
Cheaper than 40% of US stocks
Higher than 9% of US stocks
Higher than 26% of US stocks
Higher than 87% of US stocks
Higher than 32% of US stocks
Higher than 59% of US stocks
Higher than 51% of US stocks
Higher than 72% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OptimizeRx Corp. has a market value of $148.1M and an enterprise value of $145.7M.
Revenue in the twelve months to 31 Mar 2026: $107.3M. The latest quarter shrank 29.8% year on year.
Net income over the same four quarters: $6.8M, a 6.4% net margin.
Diluted earnings per share, trailing twelve months: $0.35.
Free cash flow in the twelve months to 31 Mar 2026: $14.4M, after $183K of capital spending.
Trailing P/E: 31.4×; forward P/E: 7.4× — the forward figure prices analyst consensus estimates, not reported earnings.
OptimizeRx Corp. employs 132 people — $813K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OptimizeRx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OptimizeRx Corp. announced the appointment of Troy Sarich, a pharma commercialization and AI expert, as a Company advisor. The announcement was made public on September 2, 2026.
Why it matters — The addition of an advisor with expertise in pharmaceutical commercialization and AI may bring specialized insight to OptimizeRx's healthcare technology offerings.
OptimizeRx reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% year over year, while adjusted EBITDA came in at $4.9 million. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
Why it matters — The 30% revenue decline marks a sharp reversal from the prior year, making the company's ability to hit its reaffirmed full-year targets a key focus for investors.
OptimizeRx Corporation held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational performance for the quarter.
Why it matters — Investors and analysts following OptimizeRx would review the earnings call transcript for updates on the company's financial health, strategic direction, and outlook.
OptimizeRx Corp. reported quarterly earnings of $0.16 per share for the second quarter, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share in the same quarter a year ago.
Why it matters — An earnings beat over the consensus estimate signals OptimizeRx outperformed analyst expectations for the quarter, which is relevant for investors tracking the company's results.
OptimizeRx Corp. announced that Andy D'Silva will become its next Chief Financial Officer and Heather Favazza will serve as Chief Accounting Officer, both effective January 1, 2027. The appointments are intended to support the company's next phase of growth.
Why it matters — An OPRX watcher would care because the new finance leadership appointments signal the company's preparation for its upcoming growth phase and management continuity.
The 6 Wall Street analysts covering OptimizeRx Corp. have a median 12-month price target of $11, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OptimizeRx Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OptimizeRx Corp. 83 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, OptimizeRx Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (89 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +38.4% from the last close, and Ticker Nerd's factor model ranks OptimizeRx Corp. 83 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OptimizeRx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.
OptimizeRx Corp. returned -54.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services.
The most recent item we track (GlobeNewsWire, 2 Sept 2026): "OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor". OptimizeRx Corp. announced the appointment of Troy Sarich, a pharma commercialization and AI expert, as a Company advisor. The announcement was made public on September 2, 2026.
OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services. Its platform is designed to deliver timely clinical, educational, and access-related information at the point of care, supporting communication across pharmaceutical manufacturers, providers, and patients. The company operates within the healthcare information services and digital health market, where it plays a role in improving how treatment information and support resources are shared in clinical settings. Founded in 2006 and headquartered in Waltham, Massachusetts, OptimizeRx Corporation focuses on technology-enabled solutions for the healthcare communications ecosystem.
CEO Mr. Stephen L. Silvestro · 132 employees · United States · https://www.optimizerx.com
